课题基金 / 基金详情

Ureaplasmas in acute and persistent urethritis: clinical implications

Ureaplasmas in acute and persistent urethritis: clinical implications
解脲支原体在急性和持续性尿道炎中的临床意义
批准号:
7268263
负责人:
Lisa E Manhart
金额:
$37.41万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-03-01 至 2010-02-28

项目摘要

项目成果

Lisa E Manhart的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Project Summary. Nongonococcal urethritis (NGU) is the most common sexually transmitted disease syndrome seen in men in the United States, yet up to 50% of cases have no defined etiology. Even less is known about the etiology of persistent or recurrent urethritis, which is also frequent. Ureaplasma urealyticum may be responsible for some of these idiopathic cases, but evidence regarding pathogencity of the organism and the degree to which it is associated with acute or persistent NGU is conflicting. Similar to the serovars of Chlamydia trachomatis, Ureaplasma serovars may exhibit varying degrees of pathogenicity, and recent phylogenetic analyses have demonstrated that the two major Ureaplasma biovar groupings are actually distinct species. U. parvum has been designated biovar 1, while the name U. urealyticum was retained for biovar 2. Limited data suggest that U. urealyticum (biovar 2), but not U. parvum is associated with NGU, but further studies are required to confirm this observation, as well as to assess the differential response of these two species to common antibiotic treatment regimens for NGU, and to identify the role of this organism in persistent or recurrent NGU. To address these questions, we will conduct a series of studies in conjunction with an ongoing randomized treatment trial of another genital Mycoplasma, M. genitalium. Specifically, we will 1) Assess the association of U. urealyticum (biovar 2) and U. parvum with acute NGU; 2) Determine, in our ongoing randomized double-blind trial, the relative efficacy of azithromycin and doxycycline in eradicating U. urealyticum (biovar 2) and U. parvum infection among men with NGU, and assess the relationship of the MIC of the drug used to persistence of U. urealyticum (biovar 2) and U. parvum; and 3) Evaluate the association of persistent or recurrent NGU with U. urealyticum (biovar 2) and U. parvum. Relevance. NGU is the subject of over 200,000 physician office visits per year (CDC, 2001), and represents a significant public health problem. The results of this study may lead to the identification of an additional cause of this syndrome, provide guidance on treatment decisions, and shed light on the etiology of persistent and recurrent cases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance
  • 批准号:
    10397644
  • 项目类别:
  • 资助金额:
    $65.03万
  • 财政年份:
    2021
  • 负责人:
    Lisa E Manhart
  • 依托单位:
Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance
  • 批准号:
    10616677
  • 项目类别:
  • 资助金额:
    $61.9万
  • 财政年份:
    2021
  • 负责人:
    Lisa E Manhart
  • 依托单位:
Ureaplasmas in acute and persistent urethritis: clinical implications
  • 批准号:
    8068051
  • 项目类别:
  • 资助金额:
    $13.05万
  • 财政年份:
    2010
  • 负责人:
    Lisa E Manhart
  • 依托单位:
Mycoplasma genitalium Susceptibility and Treatment
  • 批准号:
    7962199
  • 项目类别:
  • 资助金额:
    $51.83万
  • 财政年份:
    2009
  • 负责人:
    Lisa E Manhart
  • 依托单位:
海外基金